Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.
US-headquartered cancer vaccine developer VLP Therapeutics secured $15m yesterday in a series A round that included chemicals producer Konishiyasu and diversified conglomerate Sojitz.
Miyako Capital, a venture capital vehicle for Kyoto University, also participated in the round, as did SK Impact Fund, RJ Fund and private investor Robert G Hisaoka, all three of which were identified as existing backers.
VLP’s lead product candidate is a cancer vaccine but it is also working on prophylactic vaccines for malaria, dengue fever and…